Morgan Stanley Veracyte, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Veracyte, Inc. stock. As of the latest transaction made, Morgan Stanley holds 617,682 shares of VCYT stock, worth $19.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

617,682

Previous 710,588 13.07%

Holding current value

$19.2 Million

Previous $24.2 Million 1.15%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$31.92 - $44.4 $2.97 Million - $4.13 Million	-92,906 Reduced 13.07%	617,682 $24.5 Million
Q3 2024 Nov 14, 2024	BUY	$21.0 - $35.25 $4.94 Million - $8.29 Million	235,207 Added 49.48%	710,588 $24.2 Million
Q2 2024 Oct 17, 2024	SELL	$18.86 - $23.55 $551,447 - $688,578	-29,239 Reduced 5.79%	475,381 $10.3 Million
Q2 2024 Aug 14, 2024	SELL	$18.86 - $23.55 $551,447 - $688,578	-29,239 Reduced 5.79%	475,381 $10.3 Million
Q1 2024 Oct 17, 2024	BUY	$21.0 - $29.1 $614,019 - $850,854	29,239 Added 6.15%	504,620 $11.2 Million
Q1 2024 Aug 16, 2024	SELL	$21.0 - $29.1 $1.83 Million - $2.54 Million	-87,115 Reduced 14.72%	504,620 $11.2 Million
Q1 2024 May 15, 2024	SELL	$21.0 - $29.1 $1.83 Million - $2.54 Million	-87,115 Reduced 14.72%	504,620 $11.2 Million
Q4 2023 Aug 16, 2024	BUY	$19.72 - $28.68 $2.29 Million - $3.34 Million	116,354 Added 24.48%	591,735 $16.3 Million
Q4 2023 Feb 13, 2024	BUY	$19.72 - $28.68 $6.02 Million - $8.75 Million	305,075 Added 106.42%	591,735 $16.3 Million
Q3 2023 Nov 15, 2023	SELL	$22.33 - $29.92 $7.08 Million - $9.49 Million	-317,156 Reduced 52.53%	286,660 $6.4 Million
Q2 2023 Aug 14, 2023	BUY	$20.96 - $26.99 $5.2 Million - $6.69 Million	247,913 Added 69.66%	603,816 $15.4 Million
Q1 2023 May 15, 2023	SELL	$20.58 - $27.89 $3.87 Million - $5.24 Million	-187,939 Reduced 34.56%	355,903 $7.94 Million
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $1.38 Million - $2.71 Million	90,412 Added 19.94%	543,842 $12.9 Million
Q3 2022 Nov 14, 2022	SELL	$16.58 - $27.9 $189,161 - $318,311	-11,409 Reduced 2.45%	453,430 $7.53 Million
Q2 2022 Oct 27, 2022	BUY	$15.45 - $29.52 $371,340 - $709,513	24,035 Added 5.45%	464,839 $9.25 Million
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $371,340 - $709,513	24,035 Added 5.45%	464,839 $9.25 Million
Q1 2022 Oct 27, 2022	SELL	$21.94 - $42.51 $527,327 - $1.02 Million	-24,035 Reduced 5.17%	440,804 $12.2 Million
Q1 2022 May 13, 2022	BUY	$21.94 - $42.51 $3.34 Million - $6.48 Million	152,402 Added 52.84%	440,804 $12.2 Million
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $3.83 Million - $5.7 Million	106,031 Added 58.14%	288,402 $11.9 Million
Q3 2021 Nov 15, 2021	BUY	$35.62 - $52.97 $6.5 Million - $9.66 Million	182,371 New	182,371 $8.47 Million

Others Institutions Holding VCYT

# of Institutions

338

Shares Held

76.3M

Call Options Held

212K

Put Options Held

18.5K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.23B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account